China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (CR Sanjiu), a 63.22%-owned subsidiary of China Resources Pharmaceutical Group Limited (CHINARES PHARMA, 03320), released its unaudited results for the six months ended 30 June 2026.

Revenue and profitability • Revenue edged up 1.37% year on year to RMB 15.01 billion, indicating modest top-line expansion. • Net profit attributable to shareholders declined 7.96% to RMB 1.67 billion, while profit after extraordinary items fell 5.93% to RMB 1.60 billion. • Basic and diluted earnings per share both decreased 8.26% to RMB 1.00. • The weighted average return on net assets narrowed by 1.49 percentage points to 7.31%.

Balance-sheet movements • Total assets stood at RMB 55.84 billion as of 30 June 2026, down 5.03% from end-2025. • Net assets attributable to shareholders rose 2.98% to RMB 22.83 billion, reflecting retained earnings despite the profit contraction.

Cash flow • Net cash generated from operating activities reached RMB 2.42 billion, a year-on-year decrease of 15.29%, underscoring pressure on cash conversion.

Dividend proposal The board proposes a cash distribution of RMB 4.15 (tax inclusive) for every 10 shares, subject to approval at an upcoming extraordinary general meeting.

Reporting framework The figures are prepared under PRC GAAP and are unaudited; adjustments may arise upon completion of the statutory audit. The data relate solely to CR Sanjiu and do not encompass the consolidated performance of CHINARES PHARMA.